Coverage: The Meridian legal market record (editorial).
The territory includes the Middle East and North Africa as a region; no individual African country is named in the release text available to this run, so the African nexus is regional only.
| Record ID | TX-AFR-2026-0023 |
|---|---|
| Record type | Commercial IP transaction |
| Transaction type | Patent licence, Exclusive licence, In-licensing |
| IP rights | patent, regulatory data |
| Status | Signed |
| Qualifying date | 2026-07-31 |
| Sector | Life sciences · Pharmaceuticals – oncology |
| African markets | Multi-jurisdictional |
| Licensed territory | Europe, Middle East and North Africa, Australia and New Zealand. |
| Disclosed value | Not disclosed in the sources reviewed. |
| Evidence | Primary source, single · 1 source(s) |
| Last verified | 2026-10-25 |
Parties
- IMPACT Therapeutics (China): licensor
- Pharmanovia (United Kingdom): licensee
Key terms
- Interest: exclusive licence; Exclusivity: exclusive; Territorial scope: Europe, Middle East and North Africa, Australia and New Zealand
Sources
- IMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand, BioSpace (press release), 2026-07-31
Part of The Meridian’s Africa IP database. Counts, market breakdowns and rankings are derived from published records only; a record counts once. Corrections: submit evidence.


